查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1738565

全球感冒和流感药物市场规模（按类型、应用、最终用户、区域范围和预测）

Global Cold And Flu Drugs Market Size By Type (Antihistamines, Decongestants), By Application (Prescription Medications, Over-the-Counter (OTC) Medications), By End User (Hospitals and Clinics, Retail Pharmacies), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

感冒和流感药物市场规模和预测

2024 年感冒和流感药物市场规模价值 168.5 亿美元，预计到 2032 年将达到 293.9 亿美元，2026 年至 2032 年的复合年增长率为 7.20%。

  • 感冒和流感药物主要用于治疗病毒性疾病（如感冒和流感）的症状。这些药物通常包括非处方 (OTC) 减充血剂、抗组织胺药物、止咳药和止痛药，例如对乙酰胺酚和Ibuprofen。在某些情况下，复合抗病毒药物可用于治疗严重的流感症状。虽然这些药物无法治癒感染疾病，但它们确实可以缓解发烧、咳嗽、喉咙痛和鼻塞等症状，帮助患者缓解不适，并改善他们在患病期间的生活品质。
  • 随着病毒性呼吸道疾病的流行和全球人口的增长，感冒和流感药物的研发预计将蓬勃发展。药物製剂的进步，例如用于治疗多种疾病的联合治疗，预计将提高患者用药的便利性和疗效。
  • 新型抗病毒药物和疫苗的研发，以及对抗流感病毒株的研发，将推动市场成长。随着季节性流感预防和健康管理知识的不断提高，尤其是在疫情期间，预计非处方和处方笺感冒和流感药物的需求将保持在高位。远端医疗和网路药局的兴起，将增加这些药物的全球供应和消费量。

全球感冒和流感药物市场动态

影响全球感冒和流感药物市场的关键市场动态是：

关键市场驱动因素

  • 流感和感冒发病率不断上升：全球流感和感冒的高发性正在推动对感冒和流感药物的需求。根据世界卫生组织 (WHO) 的数据，每年流感疫情在全球范围内导致约 300 万至 500 万例重症患者。美国疾病管制与预防中心 (CDC) 估计，仅在美国，2010 年至 2020 年期间流感每年导致 900 万至 4,100 万人患病。
  • 人口老化加剧：老年人的免疫力较弱，更容易感染感冒和流感。根据联合国经济和社会事务部的数据，预计到2050年，全球65岁以上人口将达到15亿，几乎比2020年的7.27亿翻倍。这一人口结构变化可能会增加对感冒和流感药物的需求。
  • 医疗支出不断增长：医疗支出不断增长，尤其是在新兴国家，正在推动感冒和流感药物市场的成长。根据世界银行的数据，全球医疗支出占GDP的比例已从2000年的8.5%上升到2018年的9.8%。美国医疗保险和医疗补助服务中心(CMS)报告称，到2020年，全国医疗支出将成长9.7%，达到4.1兆美元，占GDP的19.7%。

主要问题

  • 抗病毒药物抗药性日益增强：流感病毒抗病毒药物菌株的出现，对感冒和流感药物市场构成了重大挑战。随着病毒变异，现有的抗病毒药物，例如奥司他韦（达菲），可能不再对其产生反应。这种抗药性会降低这些药物的有效性，导致病程延长和感染率上升。製药公司必须持续投入研发资金，以发现新的抗病毒药物，既耗时又耗资。为了跟上病毒变异的步伐，需要不断更新治疗方法，这可能会对医疗资源造成压力，并导致治疗延迟。
  • 药物核准的监管障碍：由于美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等机构的严格监管要求，获得新型感冒和流感药物的核准是一个漫长而复杂的过程。这些法规旨在确保药物的安全性和有效性，但它们可能会减缓创新治疗方法的推广。临床试验必须证明该药物不仅能缓解症状，而且副作用极小。应对这些监管环境可能会增加成本和上市时间，并限制公司快速应对新出现的病毒株和不断变化的患者需求的能力。
  • 副作用和安全隐患：许多感冒和流感药物，尤其是非处方药，都存在嗜睡、头晕和过敏反应等副作用。有些成分，例如减充血剂和抗组织胺药物，可能会对患有高血压或心臟病等潜在疾病的患者造成併发症。这些安全隐患可能会导致消费者避免购买某些产品或寻求替代疗法，进而影响市场需求。

主要趋势

  • 呼吸道感染疾病盛行率上升：感冒和流感等呼吸道感染疾病盛行率上升是感冒和流感药物市场的主要驱动因素之一。气候变迁、都市化进程加快以及人口老化使人们更容易受到病毒感染疾病。全球污染水平的上升正在削弱呼吸系统健康，使人们更容易受到感染疾病。这种持续的趋势增加了对非处方药和抗病毒药物的需求，因为消费者寻求即时缓解症状以保持生产力，尤其是在季节性流感流行和像COVID-19这样的大流行病期间。
  • 非处方药 (OTC) 的偏好日益增长：越来越多的消费者选择自我治疗，选择非处方感冒和流感药物。这一趋势的驱动因素包括药品供应充足、价格实惠，以及希望在无需咨询医生的情况下缓解症状。许多成药提供组合疗法，一种产品即可解决多种症状。无需处方笺即可在药局或线上平台购买这些药物，其便利性是需求成长的主要因素。
  • 联合治疗需求：越来越多的消费者寻求联合治疗透过单一剂量治疗多种症状，例如鼻塞、咳嗽和头痛。便利性是推动这一趋势的因素，患者更倾向于选择一体化解决方案，而不是针对不同症状服用多种药物。製药公司为此开发了多种症状疗法，以缓解普通感冒和流感症状。这些治疗方法可以同时控制多种症状，对生活忙碌的人群颇具吸引力，并成为感冒和流感药物市场的主要驱动力。

目录

第一章全球感冒与流感药物市场介绍

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章 全球感冒流感药物市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

第五章全球感冒和流感药物市场（按类型）

  • 概述
  • 抗组织胺药
  • 减充血剂

6. 全球感冒和流感药物市场（按应用）

  • 概述
  • 处方药
  • 非处方药

7. 感冒和流感药物市场（按最终用户划分）

  • 医院诊所
  • 零售药局

8. 全球感冒和流感药物市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中东和非洲
    • 阿拉伯聯合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲地区

9. 全球感冒和流感药物市场的竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略

第十章 公司简介

  • Johnson & Johnson
  • GlaxoSmithKline, Pfizer
  • Novartis
  • Sanofi
  • AstraZeneca
  • Bayer
  • Reckitt Benckiser
  • Procter & Gamble
  • Mylan
  • Pfizer

第十一章 附录

  • 相关调查
简介目录
Product Code: 61559

Cold And Flu Drugs Market Size And Forecast

Cold And Flu Drugs Market size was valued at USD 16.85 Billion in 2024 and is projected to reach USD 29.39 Billion by 2032, growing at a CAGR of 7.20% from 2026 to 2032.

  • Cold and flu drugs are medical products that treat the symptoms of viral diseases, primarily the common cold and influenza. These medications often include over-the-counter (OTC) decongestants, antihistamines, cough suppressants, and pain relievers such as acetaminophen or ibuprofen. In some situations, prescription antiviral drugs are utilized to treat severe flu symptoms. While these treatments do not cure infections, they do alleviate symptoms such as fever, cough, sore throat, and nasal congestion, giving patients relief and enhancing their quality of life during the illness.
  • The market for cold and flu medications is expected to develop steadily as the prevalence of viral respiratory diseases rises and the worldwide population grows. Advances in medicine formulations, such as combination therapies that treat several ailments, are predicted to improve patient convenience and effectiveness.
  • The development of novel antiviral medicines and vaccinations to combat developing flu strains will aid market growth. With increased knowledge of seasonal flu prevention and health management, particularly during the pandemic, demand for both over-the-counter and prescription cold and flu treatments is expected to stay high. The advent of telemedicine and internet pharmacies will increase the global availability and consumption of these drugs.

Global Cold And Flu Drugs Market Dynamics

The key market dynamics that are shaping the global cold and flu drugs market include:

Key Market Drivers:

  • Increasing Incidence of Influenza and Common Cold: The high prevalence of influenza and common cold cases globally drives the demand for cold and flu medications. According to the World Health Organization (WHO), annual influenza epidemics result in about 3 to 5 million cases of severe illness worldwide. In the United States alone, the Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in 9 million to 41 million illnesses annually between 2010 and 2020.
  • Growing Aging Population: The elderly population is more susceptible to cold and flu infections due to weakened immune systems. The United Nations Department of Economic and Social Affairs reports that the global population aged 65 and above is expected to reach 1.5 billion by 2050, nearly doubling from 727 million in 2020. This demographic shift is likely to increase the demand for cold and flu medications.
  • Rising Healthcare Expenditure: Increased healthcare spending, particularly in developing countries, is driving the growth of the cold and flu drugs market. The World Bank data shows that global health expenditure as a percentage of GDP has risen from 8.5% in 2000 to 9.8% in 2018. In the United States, the Centers for Medicare & Medicaid Services (CMS) reported that national health spending grew 9.7% to reach $4.1 trillion in 2020, accounting for 19.7% of GDP.

Key Challenges:

  • Growing Resistance to Antiviral Medications: The emergence of antiviral-resistant strains of flu viruses presents a significant challenge in the cold and flu drugs market. As viruses mutate, they can become less responsive to existing antiviral treatments, such as oseltamivir (Tamiflu). This resistance diminishes the effectiveness of these drugs, leading to prolonged illness and increased transmission rates. Pharmaceutical companies must continuously invest in research and development (R&D) to discover new antiviral agents, which can be time-consuming and costly. The need for updated treatments in response to viral mutations can strain healthcare resources and lead to treatment delays.
  • Regulatory Hurdles for Drug Approval: Gaining approval for new cold and flu drugs can be a lengthy and complex process due to stringent regulatory requirements from bodies like the FDA and EMA. These regulations aim to ensure the safety and efficacy of medications but can delay the introduction of innovative treatments. Clinical trials must demonstrate not only that the drugs alleviate symptoms but also that they have minimal side effects. Navigating this regulatory landscape can increase the cost and time to market, limiting the ability of companies to swiftly respond to emerging viral strains or changing patient needs.
  • Side Effects and Safety Concerns: Many cold and flu medications, especially OTC options, are associated with side effects like drowsiness, dizziness, or allergic reactions. Certain ingredients, such as decongestants or antihistamines, can cause complications in patients with pre-existing conditions like hypertension or heart disease. These safety concerns may lead consumers to avoid certain products or seek alternative treatments, thereby affecting market demand.

Key Trends:

  • Rising Prevalence of Respiratory Infections: The increasing incidence of respiratory infections, such as colds and the flu, is one of the primary drivers of the cold and flu drugs market. Changes in climate, growing urbanization, and an aging population contribute to higher susceptibility to viral infections. The global rise in pollution levels weakens respiratory health, making individuals more prone to infections. This ongoing trend increases the demand for over-the-counter medications and antiviral drugs, as consumers seek immediate relief from symptoms to maintain productivity, particularly during seasonal flu outbreaks and pandemics like COVID-19.
  • Growing Preference for Over-the-counter (OTC) Drugs: There is a growing shift toward self-medication, with consumers increasingly opting for OTC cold and flu drugs. This trend is driven by factors like easy accessibility, affordability, and the desire to manage symptoms without visiting healthcare professionals. Many OTC medications offer combination treatments, addressing multiple symptoms in a single product. The convenience of purchasing these drugs at pharmacies or online platforms without a prescription has contributed significantly to their rising demand
  • Demand for Combination Therapies: Consumers are increasingly seeking combination therapies that address multiple symptoms such as congestion, cough, and headaches in a single dose. This trend is driven by the convenience factor, as patients prefer all-in-one solutions rather than taking multiple drugs for different symptoms. Pharmaceutical companies have responded by developing multi-symptom medications that offer relief for common cold and flu symptoms. The efficiency of these treatments in managing several symptoms simultaneously appeals to individuals with busy lifestyles, making them a significant driver of the cold and flu drugs market.

Global Cold And Flu Drugs Market Regional Analysis

Here is a more detailed regional analysis of the global cold and flu drugs market:

North America:

  • North America's dominance in the cold and flu drugs market, including the high incidence of respiratory illnesses and an advanced healthcare infrastructure. The United States alone experiences millions of flu cases annually, with the CDC reporting an average of 9 million to 45 million influenza cases each year. This, combined with widespread access to healthcare and over-the-counter (OTC) medications, creates a robust demand for cold and flu treatments.
  • The aging population in North America, which is more vulnerable to respiratory infections, fuels the need for effective and accessible cold and flu drugs. Increased awareness around self-medication for minor ailments and the availability of OTC products further support the market's growth.
  • The cold and flu drugs market is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2028. Heightened awareness due to the COVID-19 pandemic has led to a surge in demand for respiratory illness treatments, further boosting the market. Significant investments in research and development, like the NIH's allocation of $484 million for influenza research in 2023, underline the region's commitment to advancing respiratory treatments.

Asia Pacific:

  • The cold and flu drugs market in the Asia Pacific region is experiencing rapid growth. The region's large and expanding population, which accounts for about 60% of the global population, plays a central role in the market's expansion. Rising urbanization and increased pollution levels contribute to a higher incidence of respiratory illnesses, fueling the demand for cold and flu medications. The growing middle class and rising disposable incomes across the region enable more people to invest in healthcare products, including over-the-counter (OTC) medications. Southeast Asia, in particular, has seen annual healthcare expenditure growth rates between 6-12%, highlighting a significant increase in healthcare access and spending.
  • Another critical driver is the region's aging population, particularly in East Asia and the Pacific, where the percentage of people aged 60 and above is expected to rise from 13.8% in 2020 to 27.6% by 2050. Older adults are more vulnerable to respiratory infections, increasing the demand for cold and flu drugs. The region's expanding healthcare infrastructure, government initiatives to improve healthcare access, and the rise of e-commerce platforms have made cold and flu medications more accessible.

Global Cold And Flu Drugs Market: Segmentation Analysis

The Global Cold And Flu Drugs Market is Segmented on the basis of Type, Application, End User, And Geography.

Cold And Flu Drugs Market, By Type

  • Antihistamines
  • Decongestants

Based on Type, the market is fragmented into Antihistamines and decongestants. Antihistamines dominate due to their widespread use in managing symptoms such as sneezing, runny nose, and watery eyes, which are common in colds and flu. They are a key component in many over-the-counter cold remedies and are favored for their ability to provide quick relief from allergy-like symptoms associated with viral infections. Decongestants are a rapidly growing segment, driven by the rising demand for medications that relieve nasal congestion and sinus pressure, particularly during flu seasons. Decongestants are often sought after for their effectiveness in reducing inflammation and easing breathing, making them essential in cold and flu treatment.

Cold And Flu Drugs Market, By Application

  • Prescription Medications
  • Over-the-Counter (OTC) Medications

Based on Application, the market is divided into Prescription Medications and over-the-counter (OTC) Medications. Over-the-counter (OTC) Medications dominate due to their ease of accessibility and wide availability without the need for a doctor's prescription. Consumers prefer OTC medications for immediate relief from common cold and flu symptoms, making them the go-to choice during seasonal outbreaks. This segment is driven by consumer awareness and the convenience of purchasing from pharmacies, supermarkets, and online platforms. Prescription Medications are rapidly growing, particularly for severe or persistent cases that require more specialized treatments.

Cold And Flu Drugs Market, By End User

  • Hospitals and Clinics
  • Retail Pharmacies

Based on End User, the market is segmented into Hospitals and Clinics, and Retail Pharmacies. Retail Pharmacies dominate due to their accessibility and convenience for consumers seeking over-the-counter medications. Retail pharmacies are widely available, making them the first point of contact for people looking for quick relief from cold and flu symptoms. The rise of online pharmacies has further fueled this segment's growth. Hospitals and Clinics represent a rapidly growing segment, particularly for more severe cases requiring prescription medications or treatment for complications. Increased healthcare visits during flu seasons and the growing preference for professional consultations in complex cases are driving the demand in this segment.

Cold And Flu Drugs Market, By Geography

  • North America
  • Asia Pacific
  • Europe
  • Rest of the world
  • On the basis of geographical analysis, the Global Cold And Flu Drugs Market is classified into North America, Asia Pacific, Europe, and Rest of the world. North America stands out as a dominant region due to its advanced healthcare system, high awareness of cold and flu treatments, and strong consumer demand for over-the-counter drugs. Asia Pacific is experiencing rapid growth, driven by increasing healthcare access, rising disposable incomes, and a growing population.

Key Players

The "Global Cold And Flu Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Johnson & Johnson, GlaxoSmithKline, Pfizer, Novartis, Sanofi, AstraZeneca, Bayer, Reckitt Benckiser, Procter & Gamble, and Mylan. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Cold And Flu Drugs Market Recent Developments
  • In September 2023, BMS disclosed that as part of a strategic license and partnership to create and market obexelimab, a brand-new, bi-functional antibody for autoimmune disorders, it will pay Zenas BioPharma $50 million upfront.
  • In May 2022, Nature's Way Products, LLC, announced a significant expansion of its Green Bay, Wisconsin, Gummy factory. Incorporating production, packaging, and warehouse space, the development will increase the present 80,000 square feet by 116,000 square feet. Early summer was the planned start date, and the project should be finished by the end of the third quarter of 2023.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL COLD AND FLU DRUGS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL COLD AND FLU DRUGS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porter's Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL COLD AND FLU DRUGS MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Antihistamines
  • 5.3 Decongestants

6 GLOBAL COLD AND FLU DRUGS MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Prescription Medications
  • 6.3 Over-the-Counter (OTC) Medications

7 COLD AND FLU DRUGS MARKET, BY END USER

  • 7.1 Hospitals and Clinics
  • 7.2 Retail Pharmacies

8 GLOBAL COLD AND FLU DRUGS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 The U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 The U.K.
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 7.5.3 Rest of LATAM
  • 8.6 Middle East and Africa
    • 8.6.1 UAE
    • 8.6.2 Saudi Arabia
    • 8.6.3 South Africa
    • 8.6.4 Rest of the Middle East and Africa

9 GLOBAL COLD AND FLU DRUGS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Johnson & Johnson
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 GlaxoSmithKline, Pfizer
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Novartis
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Sanofi
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 AstraZeneca
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Bayer
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Development
  • 10.7 Reckitt Benckiser
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Procter & Gamble
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Development
  • 10.9 Mylan
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Development
  • 10.10 Pfizer
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Development

11 Appendix

  • 11.1 Related Research